Early Corticosteroid Therapy for Mycoplasma pneumoniae Pneumonia Irrespective of Used Antibiotics in Children
Open Access
- 22 May 2019
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 8 (5), 726
- https://doi.org/10.3390/jcm8050726
Abstract
Antibiotics’ effect on Mycoplasma pneumoniae (MP) infection still remains controversial. A prospective study of 257 children with MP pneumonia during a recent epidemic (2015–2016) was conducted. All MP pneumonia patients were treated with corticosteroids within 24–36 h after admission. Initially, oral prednisolone (1 mg/kg) or intravenous methylprednisolone (IVMP; 1–2 mg/kg) was administered for mild pneumonia patients, and IVMP (5–10 mg/kg/day) for severe pneumonia patients. If patients showed a persistent fever for 36–48 h or disease progression, additive IVMP (5 mg/kg or 10 mg/kg) was given. Thirty-three percent of patients received only a broad-spectrum antibiotic without a macrolide. The mean age and the male-to-female ratio was 5.6 ± 3.1 years and 1:1, respectively. Seventy-four percent of patients showed immediate defervescence within 24 h, and 96% of patients showed defervescence within 72 h with improvements in clinical symptoms. Three percent of patients (8/257) who received additive IVMP also showed clinical improvement within 48 h without adverse reactions. There were no clinical or laboratory differences between patients treated with a macrolide (n = 172) and without (n = 85). Early corticosteroid therapy might reduce disease morbidity and prevent disease progression in MP pneumonia patients without side effects, and antibiotics may have limited effects on MP infection.This publication has 47 references indexed in Scilit:
- Macrolide Resistance ofMycoplasma pneumoniae,South Korea, 2000–2011Emerging Infectious Diseases, 2013
- Therapeutic Efficacy of Macrolides, Minocycline, and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Pediatric PatientsAntimicrobial Agents and Chemotherapy, 2013
- Mycoplasma pneumoniaepneumonia in childrenKorean Journal of Pediatrics, 2012
- The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort studyBMC Infectious Diseases, 2011
- Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: A need for early immune-modulators for severe casesMedical Hypotheses, 2011
- Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virusCritical Care, 2011
- High Prevalence of Macrolide Resistance inMycoplasma pneumoniaeIsolates from Adult and Adolescent Patients with Respiratory Tract Infection in ChinaClinical Infectious Diseases, 2010
- Difference of clinical features in childhood Mycoplasma pneumoniae pneumoniaBMC Pediatrics, 2010
- Effectiveness of β lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysisBMJ, 2005